Management of Symptomatic Hypocalcemia
For symptomatic hypocalcemia, immediately administer 10-20 mL of 10% calcium gluconate (90-180 mg elemental calcium) in 50 mL of 5% dextrose intravenously over 10-20 minutes with ECG monitoring, followed by a continuous infusion of calcium gluconate at 0.5-1.5 mg/kg/h over 8-10 hours. 1
Acute Management Algorithm
Step 1: Recognize Symptomatic Hypocalcemia
Look for these specific clinical manifestations (in order of severity):
- Mild: paresthesias (perioral, fingers, toes)
- Moderate: carpal or pedal spasm, positive Chvostek's or Trousseau's signs
- Severe: laryngospasm, seizures, or malignant arrhythmias 1, 2
Critical point: Severity depends on both the absolute calcium level AND the rate of decline—rapid drops cause more severe symptoms even at higher calcium levels 2.
Step 2: Initial IV Bolus
- Give 1-2 ampules of 10% calcium gluconate (each 10 mL ampule contains 2.2 mmol elemental calcium) 3
- Dilute in 50-100 mL of 5% dextrose
- Infuse over 10-20 minutes with continuous ECG monitoring 1, 3
- Repeat this bolus until symptoms resolve 3
Alternative if central line available: Calcium chloride can be used (more irritant to peripheral veins). Use 4.4 mL of 7.35% calcium chloride or 2.2 mL of 14.7% calcium chloride as equivalent to 10 mL of 10% calcium gluconate 3.
Step 3: Continuous Infusion
After initial bolus:
- Dilute 100 mL (10 ampules) of 10% calcium gluconate in 1 L of normal saline or 5% dextrose
- Infuse at 50-100 mL/h (equivalent to 0.5-1.5 mg/kg/h) 1, 3
- Continue for 8-10 hours or until underlying cause is addressed 1
- Titrate rate to maintain normocalcemia 3
Step 4: Monitor During Acute Treatment
- ECG monitoring throughout IV administration (watch for QT prolongation, arrhythmias)
- Check serum calcium every 4-6 hours during infusion
- Assess for symptom resolution
Transition to Chronic Management
Once acute symptoms are controlled, transition to oral therapy:
Oral Calcium Supplementation
- Start oral calcium supplements (dietary plus supplemental calcium)
- Typical doses: 1-3 grams elemental calcium daily in divided doses
Active Vitamin D
- Calcitriol (1,25-dihydroxyvitamin D) or analogs are the mainstay 1
- More effective than parent vitamin D (cholecalciferol/ergocalciferol) for rapid correction
- Dosing adjusted based on calcium levels
Target Goals for Chronic Management
The guideline is explicit about maintaining calcium slightly below normal or low-normal range (no more than 0.5 mg/dL below normal), NOT in the normal range 1. This prevents six key complications:
- Hypercalciuria (most common complication)
- Nephrocalcinosis/nephrolithiasis
- Hyperphosphatemia (keep calcium-phosphate product <55 mg²/dL²)
- Extraskeletal calcifications
- Renal impairment
- Symptoms of hypocalcemia
Monitoring Frequency
- During dose adjustments: Check serum calcium weekly to monthly depending on clinical stability 1
- Once stable: Check serum calcium twice yearly 1
- If hypercalciuria develops: Add 24-hour urine calcium measurements 1
Critical Pitfalls to Avoid
Check and correct magnesium deficiency: Hypomagnesemia impairs PTH secretion and calcium correction—always measure and replace magnesium concurrently 1.
Don't over-correct: Maintaining calcium in the low-normal range (not high-normal) reduces risk of hypercalciuria and renal complications 1. Aggressive normalization increases morbidity.
Avoid thiazides in specific populations: Do not use thiazide diuretics (even for hypercalciuria) in patients with autoimmune polyendocrine syndrome type 1 with adrenal insufficiency or certain forms of autosomal dominant hypoparathyroidism with Bartter's syndrome 1.
In critically ill patients: Recent evidence suggests treating only severe symptomatic hypocalcemia in ICU settings, as correction of mild-moderate hypocalcemia may paradoxically increase mortality and organ dysfunction, particularly in sepsis 4. However, this applies to critical care populations, not general symptomatic hypocalcemia.
Post-bisphosphonate risk: Patients receiving zoledronic acid or other antiresorptives with renal impairment are at high risk for severe hypocalcemia—do not discontinue calcium/vitamin D supplementation in these patients even in palliative settings 5.
Underlying Cause Investigation
While treating acutely, identify the etiology:
- Post-surgical hypoparathyroidism (most common—75% of cases) 6, 7
- Vitamin D deficiency
- Hypomagnesemia
- Chronic kidney disease
- Medications (bisphosphonates, denosumab, cinacalcet)
- Genetic causes in young patients or those with syndromic features 8
Measure: PTH, phosphate, magnesium, 25-hydroxyvitamin D, creatinine/GFR 1.